Back to results
US 8,796,427 B2Granted
Humanized anti-human NKG2A monoclonal antibody
AssigneeNovo Nordisk A/S
InventorsPetrus Johannes Louis Spee, Jianhe Chen, Søren Berg Padkjær, Jing Su, Jinchao Zhang, Jiujiu Yu
Life of this patent
Estimating the term…
Abstract
The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.
Claims6
An isolated antibody binding human CD94/NKG2A receptor and comprising
- (a) a CDR-L1 comprising SEQ ID NO:5;
- (b) a CDR-L2 comprising SEQ ID NO:6;
- (c) a CDR-L3 comprising SEQ ID NO:7;
- (d) a CDR-H1 comprising SEQ ID NO:8;
- (e) a CDR-H2 comprising SEQ ID NO:9;
- (f) a CDR-H3 comprising SEQ ID NO:10;
- (g) human VL and VH framework regions;
- and
- (h) a proline (P) residue at Kabat position 46 in the VL domain.
6 more elements
Dependencies are inferred from the claim text.